1. Trends Endocrinol Metab. 2020 Apr;31(4):269-271. doi:
10.1016/j.tem.2020.02.003.  Epub 2020 Feb 20.

Mitochondrial Complex I Inhibition by Metformin: Drug-Exercise Interactions.

Martín-Rodríguez S(1), de Pablos-Velasco P(2), Calbet JAL(3).

Author information:
(1)Department of Physical Education, University of Las Palmas de Gran Canaria, 
35017 Las Palmas de Gran Canaria, Spain; Research Institute of Biomedical and 
Health Sciences (IUIBS), 35017 Las Palmas de Gran Canaria, Spain. Electronic 
address: saulmrguez@gmail.com.
(2)Research Institute of Biomedical and Health Sciences (IUIBS), 35017 Las 
Palmas de Gran Canaria, Spain; Department of Endocrinology and Nutrition, 
Hospital Universitario de Gran Canaria Doctor Negrín, 35010 Las Palmas de Gran 
Canaria, Spain.
(3)Department of Physical Education, University of Las Palmas de Gran Canaria, 
35017 Las Palmas de Gran Canaria, Spain; Research Institute of Biomedical and 
Health Sciences (IUIBS), 35017 Las Palmas de Gran Canaria, Spain; Department of 
Physical Performance, Norwegian School of Sport Sciences, Postboks, 4014 Ulleval 
Stadion, 0806 Oslo, Norway.

Comment on
    Redox Biol. 2018 Apr;14:187-197.
    Cell Rep. 2019 Nov 5;29(6):1511-1523.e5.

Metformin has antidiabetic, anticancer, and prolongevity effects, but seems to 
interfere with aerobic training mitochondrial adaptations. The primary mechanism 
of action has been suggested to be the inhibition of mitochondrial complex I. 
Recent papers (Wang et al. and Cameron et al.), however, provide evidence to 
deny the hypothesis of a direct action of metformin on complex I.

Copyright © 2020 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.tem.2020.02.003
PMID: 32187522 [Indexed for MEDLINE]
